R&D is a fundamental asset in the growth of Stevanato Group, which invests in it about 4% of its turnover, each year. R&D also represents a dimension of Stevanato Group’s vision, allowing it to evolve from a packaging component and automated equipment supplier to a global drug-delivery-systems strategic partner with a full-service approach to bio-pharmaceutical companies.
Being involved in the customer’s drug development process from an early stage, Stevanato Group can deliver science-based innovation through various services, including:
How Stevanato Group responds to industry macro trends
Stevanato Group’s latest solutions are designed to meet both the most complex productivity and flexibility needs of biopharmaceutical companies and patient safety and quality of life. On the one hand, they focus on the continuous improvement of the EZ-fill® glass containers platform for a simplified supply chain and a reduction in the total cost of ownership for pharmaceutical companies. For this requirement, the answer is represented by the Alba® EZ-fill® platform for biological drugs and by the whole range of Nexa® containers, which are ideal for integration into drug delivery systems.
On the other hand, leveraging on its glass primary packaging, precise injection molded plastics and assembly equipment, Stevanato Group has developed the Integrated Safety System (ISS), a safety device aimed at simplifying the patient self- administration process, while preventing needle stick injuries.
It is also developing drug delivery systems, such as its proprietary cartridge-based wearable device, a discreet and easy to wear wearable, which is activated by an electronic hand held to facilitate the monitoring of timing and administration processes, while containing the cost of healthcare.